205 related articles for article (PubMed ID: 15876544)
1. Risk factors for carbamazepine elevation and toxicity following epilepsy surgery.
Hiremath GK; Kotagal P; Bingaman W; Hovinga C; Wyllie E; Morris H; Nelson D
Seizure; 2005 Jul; 14(5):312-7. PubMed ID: 15876544
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients.
El Desoky ES; Sabarinath SN; Hamdi MM; Bewernitz M; Derendorf H
J Clin Pharm Ther; 2012 Jun; 37(3):352-5. PubMed ID: 21883329
[TBL] [Abstract][Full Text] [Related]
3. Brivaracetam-induced elevation of carbamazepine epoxide levels: A post-hoc analysis from the clinical development program.
Brodie MJ; Fakhoury T; McDonough B; Colson AO; Stockis A; Elmoufti S; Whitesides J
Epilepsy Res; 2018 Sep; 145():55-62. PubMed ID: 29908435
[TBL] [Abstract][Full Text] [Related]
4. Relationships between carbamazepine-diol, carbamazepine-epoxide, and carbamazepine total and free steady-state concentrations in epileptic patients: the influence of age, sex, and comedication.
Svinarov DA; Pippenger CE
Ther Drug Monit; 1996 Dec; 18(6):660-5. PubMed ID: 8946662
[TBL] [Abstract][Full Text] [Related]
5. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy.
Carlsson KC; Hoem NO; Glauser T; Vinks AA
Clin Ther; 2005 May; 27(5):618-26. PubMed ID: 15978311
[TBL] [Abstract][Full Text] [Related]
6. Response to carbamazepine in children with newly diagnosed partial onset epilepsy.
Holland KD; Glauser TA
Neurology; 2007 Aug; 69(6):596-9. PubMed ID: 17679679
[TBL] [Abstract][Full Text] [Related]
7. Comparison of carbamazepine rash in multiple sclerosis and epilepsy.
Shirzadi M; Alvestad S; Hovdal H; Espeset K; Lydersen S; Brodtkorb E
Acta Neurol Scand; 2012 Jan; 125(1):60-3. PubMed ID: 21668415
[TBL] [Abstract][Full Text] [Related]
8. Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: the clinical implication.
Kong ST; Lim SH; Chan E; Ho PC
J Clin Pharmacol; 2014 Feb; 54(2):225-33. PubMed ID: 23996245
[TBL] [Abstract][Full Text] [Related]
9. Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients.
Zeng K; Wang X; Xi Z; Yan Y
Clin Neurol Neurosurg; 2010 May; 112(4):291-5. PubMed ID: 20071075
[TBL] [Abstract][Full Text] [Related]
10. Carbamazepine and its epoxide: an open study of efficacy and side effects after carbamazepine dose increment in refractory partial epilepsy.
Semah F; Gimenez F; Longer E; Laplane D; Thuillier A; Baulac M
Ther Drug Monit; 1994 Dec; 16(6):537-40. PubMed ID: 7878690
[TBL] [Abstract][Full Text] [Related]
11. [Carbamazepine presence in plasma lipoproteins].
Szymańska-Shawkat E; Dyderski S; Dobrowolska E; Steinborn B
Neurol Neurochir Pol; 2000; 34 Suppl 1():61-6. PubMed ID: 10768146
[TBL] [Abstract][Full Text] [Related]
12. New statistical method for analyzing time to first seizure: example using data comparing carbamazepine and valproate monotherapy.
Cowling BJ; Shaw JE; Hutton JL; Marson AG
Epilepsia; 2007 Jun; 48(6):1173-8. PubMed ID: 17553118
[TBL] [Abstract][Full Text] [Related]
13. Effect of plasma exchange on carbamazepine levels in a patient with myasthenia gravis and epilepsy.
Siddiqi ZA; Holt A; Ahmed SN
Epilepsia; 2005 Nov; 46(11):1841-2. PubMed ID: 16302866
[TBL] [Abstract][Full Text] [Related]
14. Implications of metabolic parameters of carbamazepine in the therapeutic monitoring of Tunisian patients with epilepsy.
Chbili C; Hassine A; Ben Amor S; Nouira M; Ben Ammou S; Saguem S
Rev Neurol (Paris); 2016; 172(4-5):313-7. PubMed ID: 27062293
[TBL] [Abstract][Full Text] [Related]
15. Oxcarbazepine-induced hyponatremia and the regulation of serum sodium after replacing carbamazepine with oxcarbazepine in children.
Holtmann M; Krause M; Opp J; Tokarzewski M; Korn-Merker E; Boenigk HE
Neuropediatrics; 2002 Dec; 33(6):298-300. PubMed ID: 12571784
[TBL] [Abstract][Full Text] [Related]
16. Patterns of care, outcomes, and direct health plan costs of antiepileptic therapy: a pharmacoeconomic analysis of the available carbamazepine formulations.
Garnett WR; Gilbert TD; O'Connor P
Clin Ther; 2005 Jul; 27(7):1092-103. PubMed ID: 16154489
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of therapeutic drug monitoring of antiepileptic drugs.
Irshaid YM; Hamdi AA; Al Homrany M
Int J Clin Pharmacol Ther; 2003 Mar; 41(3):126-31. PubMed ID: 12665161
[TBL] [Abstract][Full Text] [Related]
18. Conversion from carbamazepine or oxcarbazepine to topiramate in adolescents and adults with epilepsy.
Kowalik A; Rimpau W; Adam H; Kühn F; van Oene J; Schreiner A; Bogdanow M; Schauble B;
Acta Neurol Scand; 2008 Mar; 117(3):159-66. PubMed ID: 18218062
[TBL] [Abstract][Full Text] [Related]
19. [The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate].
Hernández-Fustes OJ; Marcourakis T; de Bittencourt PR
Rev Neurol; 1999 Jun 1-15; 28(11):1043-7. PubMed ID: 10390769
[TBL] [Abstract][Full Text] [Related]
20. Correlation between plasma carbamazepine-10,11-epoxide concentration and drug side-effects in children with epilepsy.
Schoeman JF; Elyas AA; Brett EM; Lascelles PT
Dev Med Child Neurol; 1984 Dec; 26(6):756-64. PubMed ID: 6440825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
